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COST 016/17
DECISION
Subject: Memorandum of Understanding for the implementation of the COST Action
“European Network on Understanding Gastrointestinal Absorption-related
Processes” (UNGAP) CA16205
The COST Member Countries and/or the COST Cooperating State will find attached the Memorandum of
Understanding for the COST Action European Network on Understanding Gastrointestinal Absorption-
related Processes approved by the Committee of Senior Officials through written procedure on 23 June
2017.
MEMORANDUM OF UNDERSTANDING
For the implementation of a COST Action designated as
COST Action CA16205
EUROPEAN NETWORK ON UNDERSTANDING GASTROINTESTINAL ABSORPTION-RELATED
PROCESSES (UNGAP)
The COST Member Countries and/or the COST Cooperating State, accepting the present Memorandum of
Understanding (MoU) wish to undertake joint activities of mutual interest and declare their common
intention to participate in the COST Action (the Action), referred to above and described in the Technical
Annex of this MoU.
The Action will be carried out in accordance with the set of COST Implementation Rules approved by the
Committee of Senior Officials (CSO), or any new document amending or replacing them:
a.  “Rules for Participation in and Implementation of COST Activities” (COST 132/14);
b.  “COST Action Proposal Submission, Evaluation, Selection and Approval” (COST 133/14);
c.  “COST Action Management, Monitoring and Final Assessment” (COST 134/14);
d.  “COST International Cooperation and Specific Organisations Participation” (COST 135/14).
The main aim and objective of the Action is to expand our knowledge on intestinal drug absorption to make
drug development and clinical treatment more knowledge-driven by focussing on four key topics: specific
patient populations, regional differences in absorption along the gastrointestinal tract, advanced
formulations and the food-drug interface. This will be achieved through the specific objectives detailed in
the Technical Annex.
The economic dimension of the activities carried out under the Action has been estimated, on the basis of
information available during the planning of the Action, at EUR 76 million in 2016.
The MoU will enter into force once at least five (5) COST Member Countries and/or COST Cooperating
State have accepted it, and the corresponding Management Committee Members have been appointed, as
described in the CSO Decision COST 134/14.
The COST Action will start from the date of the first Management Committee meeting and shall be
implemented for a period of four (4) years, unless an extension is approved by the CSO following the
procedure described in the CSO Decision COST 134/14.
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TECHNICAL ANNEX
OVERVIEW
Summary
Oral administration is the most common drug delivery route. Absorption of a drug from the gut into the
bloodstream involves disintegration of the dosage form, dissolution of the API, and transport across the gut
wall. The efficiency of these processes is determined by highly complex and dynamic interactions between
the gastrointestinal tract, the dosage form and the API.
The fraction absorbed of the drug is affected by various factors including physiological variables,
pathological conditions, local differences in gut permeability, the intraluminal behaviour of the formulation,
and food effects. This complex interplay determines drug delivery performance and may cause large
interindividual variability, but is poorly understood. Furthermore, comparison between drug absorption
studies is hampered due to knowledge fragmentation and lack of standardisation across pharmaceutical
subdisciplines. As a result, the available knowledge is underutilized in drug development and clinical
treatment.
The European Network on Understanding Gastrointestinal Absorption-related Processes (UNGAP) is
a multidisciplinary Network of scientists aiming to advance the field of intestinal drug absorption by
focussing on 4 major challenges: (i) differences between specific patient populations, (ii) regional
differences along the gastrointestinal tract, (iii) the intraluminal behaviour of advanced
formulations, and (iv) the food-drug interface. The integration of knowledge, combined with the
exchange of best practices across sectors and disciplines, will help improve our understanding of intestinal
drug absorption and spur future developments in the field. The Action also aims to advance the career of
young, talented researchers from across Europe, thereby strengthening Europe’s leading position in
pharmaceutical sciences.
Areas of Expertise Relevant for the Action
● Basic medicine: Pharmacology, pharmacogenomics, drug
discovery and design, drug therapy
Keywords
● gastrointestinal tract
● oral drug absorption
● individual variability
● methodology, technology and assays
● (patho)physiology
Specific Objectives
To achieve the main objective described in this MoU, the following specific objectives shall be
accomplished:
Research Coordination
● Stimulate interdisciplinary dialogue and sustainable public-private partnerships by organising discussions
and collaborations between stakeholders from different sectors and disciplines.
● Defragment the intestinal drug absorption research landscape by organising interdisciplinary discussions
and by reviewing the state-of-the-art in the field.
● Improve reproducibility and comparability of assays and results by publishing standardised protocols and
best practice guidelines.
● Expand knowledge on the challenges underpinning the scientific WGs through interdisciplinary dialogue,
the creation of new collaborations and the development of new research projects.
● Contribute to the viability and success of ongoing collaborative research projects by embedding existing
collaborative ties in a larger, sustainable Network.
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● Reflect on the impact of recent advances and emerging concepts (e.g. supersaturating drug delivery
systems) on the field of drug absorption in WG meetings and Network-wide events
● Facilitate the development of new research projects by developing a future research agenda and initiating
discussions with this specific aim.
Capacity Building
● Identify and interact with stakeholders throughout different stages of the innovation cycle: drug discovery,
drug development, regulatory decision making, and drug treatment.
● Promote access to state-of-the-art research infrastructure by compiling a list of research institutions that
posses or have access to such technology.
● Improve career perspectives of early-stage researchers, particularly in less research intensive countries,
by supporting researcher mobility and expanding professional networks.
● Facilitate scientific collaboration by organising and coordinating a sustainable Network
● Offer a balanced vision and expertise to regulatory agencies and decision makers through their
participation in the Network as external advisors and through targeted communication measures
Powered by TCPDF (www.tcpdf.org)
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1) S&T EXCELLENCE 
A) CHALLENGE 
I) DESCRIPTION OF THE CHALLENGE (MAIN AIM) 
Oral intake is the preferred route of drug administration due to its non-invasive character and 
convenience for the patient. The bioavailability of the active pharmaceutical ingredient (API) is 
an important property of oral drugs. Large interindividual variability in bioavailability exists 
across the patient population. The underlying causes of this variability are often not well 
understood. This is a major source of drug candidate and clinical treatment failure and leaves 
ample room for improvement in drug development as well as drug treatment. 
Absorption from the gastrointestinal (GI) tract into the bloodstream is a major challenge for 
orally administered drugs. Absorption involves disintegration of the dosage form, dissolution 
of the API, and transport across the gut wall. The fraction of the API absorbed is affected by 
various GI factors. Bile salt secretions have a solubilising effect, but vary greatly among healthy 
volunteers [1]. Food intake results in delayed gastric emptying and changes the composition 
of intestinal fluids, affecting drug solubility [1]. Fluctuations in gastric pH may change API 
ionisation, possibly affecting its dissolution, solubilisation and absorption [2]. Lipases and food-
derived lipids affect the behaviour of lipid-based formulations [3]. Inflammation affects the 
permeability of the gut wall [4]. Gut microbiota can affect absorption by metabolising drugs in 
the intraluminal environment [5]. Finally, the expression and activity levels of drug transporters 
and metabolizing enzymes can differ among populations and are important determinants of 
pharmacokinetics [6]. These are just a few examples of variables affecting intestinal drug 
absorption. The complex interplay of variables has repercussions on overall drug 
absorption, but a thorough understanding is lacking. Many studies focus on only one or a 
few drugs and extrapolation to other drugs is complicated. Even comparison between studies 
with the same drugs is often hampered by a lack of standardisation in methodologies across 
the pharmaceutical subdisciplines. In addition, high quality data corresponding to specific 
patient populations are scarce. As a result, the data is often insufficient to efficiently guide 
patient treatment or drug development, forcing clinicians and drug developers to fall back on 
empirical trial-and-error methods and rules of thumb. However, successful methods from the 
past hold no guarantee for the future, as the number of APIs with challenging physicochemical 
properties, such as low aqueous solubility (Biopharmaceutics Classification System (BCS) 
class II and IV compounds), low stability or permeability (e.g. BCS class III and IV), or high 
molecular weight (peptides, proteins), has increased dramatically. Therefore, there is a need 
to strengthen the oral drug absorption knowledge base to make drug development and 
clinical treatment move from empirically- to knowledge-driven. 
The European Network on Understanding Gastrointestinal Absorption-related 
Processes (UNGAP) aims to provide this solid knowledge base by creating a multidisciplinary 
Network of scientists. The Network will focus on 4 major challenges in intestinal drug 
absorption, each corresponding to a scientific working group (WG) (Fig. 1). WG 1 will focus on 
specific patient populations and their differences in oral drug absorption. WG 2 will focus on 
regional differences along the GI tract. WG 3 will study the specific intraluminal behaviour 
of advanced formulations such as supersaturating drug delivery systems, nanoparticles, 
  
       6 
lipid-based and controlled release 
formulations. WG 4 will focus on the 
food-drug interface and study 
how food intake, specific food 
components and food-induced 
secretions affect drug absorption. 
Finally, WG 5 is a generic, cross-
cutting WG that will coordinate all 
dissemination, exploitation and 
public engagement activities. All 
scientific WGs are interdisciplinary 
and challenge-driven. Scientists 
from various pharmaceutical and 
medical subdisciplines in academia,  
industry and clinical practice will interact to defragment knowledge, discuss the latest 
developments in the field and identify solutions. Importantly, multiple connections between the 
WGs exist. For example, efficient treatment of patients with colitis requires knowledge on 
controlled release formulations, disease-mediated alterations in colon permeability and 
formulation behaviour in the lower parts of the gut. Furthermore, translation of findings into 
clinical or industrial applications requires extensive interaction between WG 1-4 and WG 5. 
The integration of knowledge, combined with the exchange of best practices across sectors 
and disciplines will improve the current understanding of oral drug absorption, spur future 
developments, and, in the long run, help bring better pharmaceutical products and treatments 
to the patient. As such, the Action will strengthen Europe’s leading position in pharmaceutical 
sciences. 
II) RELEVANCE AND TIMELINESS 
Issues related to pharmacokinetics and bioavailability, for which drug absorption is an 
important determinant, are the third most prominent cause of oral, small-molecule drug 
candidate attrition in Phase I clinical development, clearly indicating that efficient oral drug 
delivery poses significant challenges to drug developers [7]. Considering the increasing 
number of APIs suffering from unfavourable absorption-related properties in development, it is 
likely that efficient oral drug delivery will become even more challenging in the future. 
Therefore, more effort and knowledge will be needed to bring the next generation of complex 
drugs to the market. 
Innovative oral drug delivery systems such as supersaturating formulations call for research 
into the detailed characteristics and performance of these systems. Specifically, the US Food 
and Drug Administration (FDA) calls for an evaluation of the analysis methods used to asses 
the performance of drug delivery systems and determine pharmacokinetics and bioavailability. 
In addition, the FDA highlights pharmacometrics as an area needing further investigation and 
recently launched a call on the integration of supersaturation-precipitation characteristsics into 
mechanistic oral absorption models [8, 9]. Such in silico models also have applications in the 
areas of drug safety testing and dose optimisation. The European Medicines Agency’s 
(EMA) objectives include a reduction in animal studies and support for the development of 
medicines for specific target populations for which a thorough understanding of drug and 
formulation behaviour in these populations is necessary [10]. 
This clearly indicates a need for continued research, extensive integration of knowledge and 
increased interdisciplinary and intersectoral collaboration between drug formulation 
developers, biopharmaceutical scientists, gastroenterologists and experts in the development 
and use of advanced in vitro, in/ex vivo and in silico models. The proposed Action will act as a 
catalyst in the area of intestinal drug absorption by fostering scientific collaboration between 
key players in the European Research Area and establishing links with leading experts 
worldwide. 
 
Fig. 1 UNGAP Working Group structure 
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B) SPECIFIC OBJECTIVES  
I) RESEARCH COORDINATION OBJECTIVES 
Fostering scientific excellence in the field of intestinal drug absorption is the main goal of 
UNGAP. For this purpose, an open, interdisciplinary and intersectoral network will be created. 
Specifically, the network aims to achieve the following research coordination objectives: 
 Stimulate interdisciplinary dialogue and build sustainable public-private partnerships by 
organising discussions and collaborations between actors from different sectors and 
disciplines in specific WGs. 
 Defragment the intestinal drug absorption research landscape by organising 
interdisciplinary discussions and by reviewing the state-of-the-art in the field. 
 Improve reproducibility and comparability of assays and results by publishing standardised 
protocols and best practice guidelines. 
 Expand knowledge on the challenges underpinning the scientific WGs through 
interdisciplinary dialogue, setting up  new collaborations and developing new research 
projects.  
 Contribute to the viability and success of ongoing collaborative research projects by 
embedding existing collaborative ties in a larger, sustainable Network. 
 Reflect on the impact of recent advances and emerging concepts (e.g. supersaturating drug 
delivery systems) on the field of drug absorption in WG meetings and Network-wide events.  
 Facilitate the development of new research projects by creating a future research agenda 
and initiating discussions with this specific aim. 
II) CAPACITY-BUILDING OBJECTIVES 
Leveraging and embedding scientific excellence across the European intestinal drug 
absorption research community, improving participants’ career perspectives and steering the 
future research agenda are the main capacity-building goals. These goals will be achieved 
through the following objectives:   
 Identify and interact with stakeholders throughout different stages of the innovation cycle: 
drug discovery, drug development, regulatory decision making, and drug treatment. 
Stakeholders will be identified among UNGAP members and their networks. Various 
communication tools will be used for interacting with them (see 2.2.2 for a full list). 
 Promote access to state-of-the-art research infrastructure by compiling a list of research 
institutions that posess or have access to such technology. 
 Improve career perspectives of early-career investigators (ECIs), particularly in less 
research intensive countries, by supporting researcher mobility and expanding professional 
networks. 
 Facilitate scientific collaboration by organising and coordinating a sustainable Network. 
 Offer a balanced vision and expertise to regulatory agencies and decision makers through 
their participation in the Network as external advisors and through targeted communication 
measures (see 2.2.2 for a full list). 
C) PROGRESS BEYOND THE STATE-OF-THE-ART AND INNOVATION 
POTENTIAL 
I) DESCRIPTION OF THE STATE-OF-THE-ART 
Drugs intended for oral administration often suffer from suboptimal performance. Despite the 
available knowledge and progress being made, significant knowledge gaps remain.  
WG 1. Specific patient populations.  
After oral intake, drugs encounter a constantly changing GI environment. Factors known to 
influence drug absorption include pH, gut transit time, gut motility, bile and pancreatic 
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secretions, colloidal structures and food components. However, how this dynamic environment 
affects drug absorption exactly, is poorly understood. There are only a few reports on the 
variability in drug absorption in specific patient populations (patients on proton pump 
inhibitors, after bariatric surgery, with obesity, pediatric) [11-14]. Similarly, little is 
known about alterations in gut permeability and its effects on drug absorption in 
patients suffering from intestinal disorders [15]. Furthermore, growing evidence on the 
effects of genetic variations among different ethnic groups on pharmacokinetics has 
emerged over the last decade, but a complete picture is still lacking [16]. Finally, drug 
absorption can differ considerably among different age groups [17]. Large knowledge 
gaps remain for specific age groups, especially for younger children due to technical 
and ethical limitations. This leads to a high degree of uncertainty, both in drug development 
and in drug treatment. A potential solution to this problem is the development of in vitro, in 
silico and small animal in vivo models that are able to accurately describe intestinal drug 
absorption for specific age groups.  
WG 2. Regional differences along the GI tract. 
Studies on oral drug absorption typically focus on the upper small intestine, as this is the first 
major absorptive site a drug encounters. However, it is becoming increasingly apparent 
that the upper and lower parts of the GI tract also play an important role in the overall 
drug absorption process. For example, the stomach can exert grinding forces strong 
enough to physically crush certain formulations [18, 19]. Furthermore, it has been 
shown that the gastric residence time plays an important role in the bioavailability of 
lipid-based formulations [20]. Given the steep increase in the number of patients undergoing 
bariatric surgery, it is important to understand the role of the stomach in determining overall 
drug absorption [21]. There is also renewed interest from pharmaceutical industry in the 
ileum and colon. In one study, Fadda et al. have shown an increase in pH and buffer 
capacity in intestinal fluids along the length of the GI tract [22]. Other studies have 
focussed on the composition and ultrastructure of contents in the ileum, cecum and 
ascending colon of healthy volunteers, after food intake and in patients with 
inflammatory bowel disorders [23-26]. Important knowledge gaps remain on the number 
and function of drug transporters in the ileum and colon, on the composition of colonic fluids 
and on the drug uptake and permeation process in patients with inflammatory bowel disorders 
and colonic cancer. This information is particularly important for developing formulations 
targeting drug release in the colon [27]. 
WG 3. Intraluminal behaviour of advanced formulations. 
The large number of candidate drugs with suboptimal biopharmaceutical characteristics (BCS 
II-IV) is a major hurdle for the pharmaceutical industry. Several formulation strategies have 
been developed to increase drug bioavailability such as reducing particle size, using self-
emulsifying drug delivery systems, cyclodextrins, solid dispersions and lipid-based 
formulations (reviewed in [28]). However, not every aspect of such enabling formulations is 
understood. Questions remain regarding the creation and maintenance of 
supersaturation in the gut. For instance, the effects of lipolysis on drug release from 
lipid-based formulations are unknown [29]. The penetration of the intestinal mucosa by 
nanoparticles [30], uptake of dendrimer-drug conjugates and their transepithelial 
transport [31] are not well understood. In general, the selection of formulations is based 
on in vitro tests with limited relevance to GI behaviour, or relies on animal models with 
limited predictivity for the specific patient population. This leads to poor predictivity of the 
in vivo behaviour and inefficient selection of the best drug delivery system. 
WG 4. Food-drug interface.  
Significant overlap exists between food and pharmaceutical sciences. Food intake has a major 
effect on gastric motility [32], pH, bile secretion and intestinal fluid composition (indirect food 
effects) [1]. Furthermore, specific food-drug interactions can have severe effects on drug 
absorption, as illustrated by the interactions between grapefruit juice, the OATP2B1 and P-
glycoprotein drug transporters, and CYP3A4 metabolizing enzyme [33]. Research also 
indicates pharmacokinetic interactions between drugs and nutraceuticals [34]. In addition, 
food-derived lipids can interact with lipid-based formulations [35]. For many other food 
components, the specific effects on drug absorption are unknown because of the 
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heterogeneous composition of a typical meal and the complex interplay between food 
components, the intestinal environment and the drug product. As a consequence, food 
effects, especially negative food effects, are very challenging to predict. Since 
formulations can be resistant or susceptible to food effects, this makes the decision on 
the type of formulation for optimal drug delivery very difficult. 
General: advanced methods and models to study drug absorption.  
One of the major limiting factors in tackling the abovementioned challenges, is the 
technical difficulty of accessing or visualising the GI tract. This hampers the 
development of suitable user-friendly tools to accurately mimic and study the complex 
GI environment in the lab. Fortunately, several advanced technologies are now available 
to overcome this hurdle. For example, nuclear imaging techniques have been used in 
diagnostics, clinical drug development, for monitoring disease progression, and have 
expanded the use of preclinical small animal models of disease. Preclinical nuclear imaging 
is practically non-invasive and data is acquired in real time, without the need for animal 
euthanasia, making it applicable to longitudinal studies in pharmacokinetics, drug disposition 
and metabolism [36]. Moreover, video capsule endoscopy has been used successfully in 
patients with GI disorders to visualize the gut and to study drug behaviour. Potentially, it can 
also be used for local drug delivery and for sampling of intestinal fluids [37]. Other advanced 
techniques are used for the in-depth study of formulation behaviour. For example, Surface 
Plasmon Resonance (SPR) is capable of real-time label-free monitoring of drug-living cell 
interactions [38]. Coherent anti-Stokes Raman Spectroscopy (CARS) has been used in 
biomedical sciences (e.g. lipid imaging in cancer cells) and can be used to probe drug 
distribution in dosage forms, drug and excipient release, dissolution, interactions with cells, 
and potentially dissolved drug distribution in cells. [39]. However, questions remain as to how 
the setup can be further optimized and how results from advanced dissolution testing relate to 
pharmacopoeial dissolution testing methods. Synchrotron small angle X-ray scattering can 
be used to understand the generation of colloidal phases and the behaviour of lipid-based 
formulations [40]. Computational tools addressing the impact of formulation parameters and 
suitable in vitro-in vivo  and in silico-in vivo correlations can make formulation work significantly 
more knowledge-driven. Molecular dynamics (MD) simulations have been used to study 
biological membranes, transport processes and to simulate simple surfactant systems in living 
cells, but are still relatively unexplored in the field of drug formulation and development [41].  
Similarly, pharmacometric models accurately describing the pharmacokinetics and 
pharmacodynamics of (candidate) drugs can improve drug development and drug dosing. The 
fast progress in the field of pharmacometrics has resulted in several models and software 
packages (e.g. Simcyp simulator, NONMEM, GastroPlus, PK Sim) for dose prediction, clinical 
trial design and simulation of individual GI variability. However, most of these products were 
independently developed in parallel, resulting in different capabilities, purposes, programming 
language and algorithms. As a result, comparison and exchange of different models without 
the need for extensive modification, is almost impossible in practice. Recently, the 
Pharmacometrics Markup Language (pharmML) exchange format was developed as a first 
step towards defragmentation [42]. Moreover, the widespread application of pharmacometric 
models is hampered by the limited quantity and quality of data underpinning the models. This 
results in a low confidence level for predictions concerning pediatric or geriatric patients, 
certain ethnic minorities and BCS II-IV compounds [43].  
The use of advanced methods will be key to progress the field on all 4 major challenges and 
is therefore integrated into WG 1-4.  
II) PROGRESS BEYOND THE STATE-OF-THE-ART 
Novel insight into the intraluminal behaviour of drugs and (advanced) formulations in 
specific patient populations, in the different parts of the GI tract and in the presence or 
absence of food components all contribute to improving clinical treatment and the 
development of better performing drugs. The key to achieving significant progress 
beyond the state-of-the-art lies in the interdisciplinary dialogue established in each of 
the WGs. 
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Specifically, the Action aims to improve the quality of predictive simulation tools. 
Clinicians and biopharmaceutical scientists with experience in human studies (e.g. 
endoscopy capsules, sampling of intestinal fluids) and with access to patients will 
interact with experts in the development and use of in vitro and in/ex vivo (small animal) 
models. They will be complemented by technology and software developers. The close 
interaction between technology developers and end-users will permit rapid improvements and 
a widespread implementation.  
The introduction of advanced techniques and models allowing more in-depth studies of 
drug absorption to a wider audience will  benefit the research community. For example, 
physiological effects caused by hydrodynamics, fluid volumes and food digestion are currently 
not taken into account in most in vitro models. The multi-scale approach for MD simulations 
allows time and spatial scale transformation/back-transformation, simulations of compositional 
changes and will give insight into structural rearrangements of drug delivery systems due to 
changes in intestinal fluid composition. The use of SPR to study interactions between small 
molecules and cell monolayers in physiologically relevant systems will provide valuable insight 
into interactions taking place at the gut wall. Capsule technology creates the opportunity for 
local delivery of drugs, visual inspection of gut (patho)physiology and sampling of intestinal 
fluids. The Action will compile a list of research institutions that have access to such 
technologies to promote their use. 
By bringing together gastroenterologists and pharmaceutical scientists, the Action will 
foster a two-way dialogue that will result in improved knowledge on intestinal disorders 
and their effects on drug absorption. This will guide the development of efficient new oral 
therapeutics for various disorders, most notably intestinal inflammatory diseases and other 
disorders of the GI tract. The knowhow on the disease and experimental tools provided by 
gastroenterologists will lead to new insight into gut permeability and provide new means to 
study drug absorption in the diseased gut and help design suitable formulations. Moreover, by 
interacting with clinicians, access to patients and patient samples becomes feasible. 
Clinical data on regional differences in intestinal absorption can be used by formulation 
scientists to design formulations for specific targeting of e.g. the colon, which has been 
identified by the pharmaceutical industry as an area of major interest for the development of 
new treatments. The data can also be used by computational modellers to more accurately 
predict drug and formulation behaviour in the different parts of the gut.  
Similarly, fed state data from human volunteers can be used to more accurately 
simulate food-drug interactions and to develop formulations avoiding or exploiting food 
effects. The availability of analytical methods and in vitro models to study food intake and 
composition in addition to scientific expertise on food-drug interactions and in performing 
clinical studies with human volunteers in fed and fasted state will be of great value to advance 
our knowledge in this area. 
III) INNOVATION IN TACKLING THE CHALLENGE 
A better understanding of drug absorption in specific populations such as obese, 
pediatric and geriatric patients will contribute to the development of in vitro, in silico 
and small animal models capable of predicting drug and formulation behaviour for 
these populations. For example, in-depth profiling of the GI tract in patients after bariatric 
surgery will result in information that can be used to improve in vitro models to accurately mimic 
specific, complex situations. A better understanding of GI (patho)physiology will also be 
key to develop a strategy to efficiently deliver drugs and maintain mucosal integrity in 
patients with intestinal inflammatory disorders. In particular, bringing together experts in 
intestinal inflammatory disorders with drug developers creates a platform where information 
on the disease can be used as input for drug development and where candidate drugs can be 
tested in preclinical disease models. Furthermore, by bringing together drug delivery 
scientists with experts from a major food company, the Action aims to stimulate 
scientific discussions between food and pharmaceutical sciences.  
The experimental techniques at reach within the Network allow comparison between in silico 
simulations, in vitro models and in vivo data, and facilitate in vitro-in vivo and in silico-in vivo 
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extrapolations. The introduction of advanced techniques to a new audience will result in 
multiple innovative applications such as the use of CARS to study formulation behaviour at 
a microscopic level. Furthermore, MD simulations of molecular interactions taking place in 
intestinal fluids will benefit tremendously from the Network’s interdisciplinary expertise. The 
direct interaction between theoretical scientists and scientists performing in vivo studies will 
improve the quality of simulations.  
Significant innovation is expected for computational models predicting (candidate) 
drug and formulation behaviour. The biggest bottleneck in their widespread use is the lack 
or insufficient quality of data underpinning the models. By fostering data exchange between 
members, the Action will help to overcome this limitation. Moreover, the Action will promote 
the deposition of computational models in open access repositories such as DDMoRe 
(see 1.4.2) and the use of the PharmML language to increase their dissemination and 
implementation. 
D) ADDED VALUE OF NETWORKING 
I) IN RELATION TO THE CHALLENGE 
Typically, researchers tend to focus mainly on their own area of expertise. However, 
efficient treatment of a patient with an orally administered drug is by definition the end-
result of interdisciplinary collaboration, both in drug development and in drug 
treatment. In practice, the available knowhow and expertise is often underused, due to 
insufficient and/or inefficient interaction between the different actors. To design drug delivery 
systems that efficiently interact with and take advantage of the features of the GI tract, 
exploitable knowledge on gut (patho)physiology and drug disposition in specific patient 
populations is required. This is typically the area of expertise of gastroenterologists, biomedical 
scientists, and cell biologists. Drug delivery systems are designed by formulation scientists 
with expertise in chemical and material sciences. The behaviour of new formulations can 
subsequently be assessed by biopharmaceutical scientists in computational, in vitro and in/ex 
vivo models. For this, they rely on technology developers and (bio)informaticians to provide 
the experimental tools. All these actors will engage in scientific discussions in UNGAP. 
To create a truly interdisciplinary network, the Network will structure itself in different 
WGs, each focussing on a major current challenge in oral drug absorption. This will lead 
to the optimal use of the available knowledge and means, a better understanding of drug 
disposition in specific patient populations, more profound knowledge on the specific behaviour 
of advanced formulations and on food-drug interactions. 
II) IN RELATION TO EXISTING EFFORTS AT EUROPEAN AND/OR INTERNATIONAL 
LEVEL 
The Network is composed of scientists with expertise in several disciplines related to oral drug 
absorption. To maximize efficiency and impact, links with other networks or projects will be 
sought. Specifically, the Action will seek interaction with follow-up networks and activities from 
the finished COST Action Infogest (FA1005; 2011-2015; digestion and effect of food 
components on human health), in which several UNGAP members participated. Beyond 
COST, the Action will seek to interact with the IMI projects DDMoRe (www.ddmore.eu; 2011-
2016; pharmacometrics), COMPACT (www.compact-research.org; 2012-2017; 
macromolecular therapeutics) and OrBiTo (www.orbitoproject.eu; 2012-2017; in vitro tools for 
oral drugs), the FP7 project TRANS-INT (www.trans-int.eu; 2012-2017; oral nanomedicines) 
and Horizon 2020 European Training Network PEARRL (www.pearrl.eu; 2016-2020; 
regulatory science tools). 
The Action shares links with several individual research topics of these projects, but has a 
broader composition, with scientists from academia and pharmaceutical industry, clinicians, 
technology and software developers, and regulatory authorities participating. The Network 
aims to connect scientists from different disciplines, sectors and countries that otherwise would 
not or rarely interact. For example, researchers from some European countries are 
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underrepresented in the aforementioned projects limiting their potential impact in these 
regions. By creating a true pan-European Network, UNGAP will have a leveraging effect on 
intestinal drug absorption research in these countries. Furthermore, because the Network has 
a wide scope and is not constructed with one specific research objective in mind (e.g. better 
in vitro tools), UNGAP is better suited to develop into a long-term sustainable Network 
that can respond to emerging challenges and opportunities. In this respect, the 
participation of representatives from several pharmaceutical companies will be a major 
advantage that will help identify important research areas and facilitate pre-competititve 
collaboration and open innovation. Finally, the aforementioned projects are all scheduled to 
end in the following years and it is important that existing collaborative ties are re-embedded 
in a sustainable Network, where they can be maintained and expanded. 
Beyond Europe, the American Association for Pharmaceutical Sciences (AAPS) is the 
biggest professional society in pharmaceutical sciences. By carefully selecting network 
participants from the USA, the Network will be able to interact with AAPS and effectively reach 
a global audience. Specifically, the Action will seek to establish links with the AAPS focus 
group on oral absorption (www.aaps.org/FocusGroups/).  
2) IMPACT 
A) EXPECTED IMPACT 
I) SHORT-TERM AND LONG-TERM SCIENTIFIC, TECHNOLOGICAL, AND/OR 
SOCIOECONOMIC IMPACTS 
The proposed Action will ensure a pooling of specialized means, resources and know-how that 
will result in an overall increase in research quality and have impact on a number of areas.  
The main expected scientific impact is the improved knowledge on the specific 
challenges (specific patient populations, food-drug interactions, regional differences, 
advanced formulations) and the integration thereof to obtain a holistic view. For 
example, new insight into food-drug interactions and drug behaviour in specific patient 
populations can influence dosing regimens and formulation design. Likewise, information on 
changing parameters along the GI tract (e.g. pH), and the in vivo behaviour of advanced 
formulations can be used by drug developers to improve drug delivery systems. A more 
patient-centric and knowledge-driven drug development process will have the advantage of 
reducing animal and clinical studies. It will also contribute to the development of dosing 
regimens that are optimized for specific patient populations, thus improving clinical outcome. 
Moreover, the expanded knowledge can help improve the regulatory decision making process. 
Technological impact will be achieved at different levels. At the level of the end-user, 
the Network will act as a troubleshooting platform by bringing them in direct contact with 
technology developers, who can help solve the problems they are faced with in research 
practice. At the level of technology developers, direct feedback from end-users will spur 
technological improvement. At the level of the Network itself, the mix of software and 
technology developers and end-users is ideal to develop and/or improve in vitro, in/ex 
vivo and in silico tools and models and move rapidly across technological and 
intellectual barriers. These tools and models will be made available to the wider research 
community by depositing them in open access repositories and through pro-active 
dissemination in the research community. They will also be communicated to clinicians and 
regulatory authorities for implementation in dose adjustment strategies and in the regulatory 
decision making process. In this respect, the biowaiver procedure by the FDA, EMA and the 
World Health Organisation based on the Biopharmaceutics Classification System presents an 
excellent example of how a research achievement can become part of the regulatory decision 
making process [44, 45]. At the level of the wider research community, the Action will 
improve comparability and reproducibility of assays and results accross different 
disciplines by compiling a catalogue of standardized experimental methods, protocols and 
best practice guidelines. This will allow the development of a consistent data set and will start 
an interactive, positive feedback loop for assay monitoring and improvement. This step 
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towards standardization of drug development research will benefit academic researchers and 
the pharmaceutical industry, who generate and work with the data, regulatory authorities, who 
review the data, and eventually also clinicians and patients, who prescribe and take the drugs 
respectively.  
The Action will also generate socioeconomic impact. Firstly, for the scientists involved, it 
presents an opportunity to expand their professional network. This benefit is emphasized 
by the fact that the Network looks specifically for upcoming research talent and seeks to 
connect quality research groups from less research intensive countries with leading research 
groups and companies from Europe, the USA and Australia. Secondly, the abovementioned 
scientific and technological benefits may be used to improve the drug development 
process, making it more cost-effective and less time-consuming, thus, potentially having major 
socioeconomic benefits in the long run. Thirdly, the use of pharmacometric models for 
treatment individualisation will improve clinical outcome and benefit the patient’s health. 
In this respect, it should be noted that the historical success of oral drug administration is 
partially based on mass production of fixed dosage units. For drugs with a large therapeutic 
window, it is likely that this will stay the preferred, economically advantageous route. However, 
for (new) drugs with a high development or manufacturing cost or a narrow therapeutic window, 
treatment individualisation will be preferable from both an economic and therapeutic point of 
view. 
B) MEASURES TO MAXIMISE IMPACT 
I) PLAN FOR INVOLVING THE MOST RELEVANT STAKEHOLDERS 
The Action aims to set up and maintain a pan-European network of scientists focussing on oral 
drugs, by removing scientific, technological and geographical barriers. As a consequence, 
many stakeholders are connected to this Action (listed in Table 1). They will be involved 
through active participation in the Action or via targeted communication measures (Table 1, 
Section 2.2.2).Biopharmaceutical scientists constitute the majority of the Network. Their 
main interest is to better understand intraluminal drug and formulation behaviour and overall 
drug absorption. They will contribute to and benefit from knowledge defragmentation, the 
insight obtained and the scientific discussions in the WGs. Formulation scientists will exploit 
this knowledge to develop better performing drug products. They are complemented by 
computational modellers, who use the obtained knowledge as input for computational 
models that can guide formulation design and dose optimisation. For technology developers 
the main interest is the direct interaction with technology end-users enabling an efficient 
dialogue that permits faster technological advancement. The (long-term) end-users benefitting 
from the Network are the pharmaceutical industry on the one hand and clinicians and patients 
on the other hand. For the pharmaceutical industry, the goal is to develop better drugs in a 
more cost-effective and less time-consuming way. For this purpose, knowledge 
defragmentation, standardized protocols and improved simulation tools will be important. 
Clinicians and patients will benefit from models that can guide dose optimisation and improve 
treatment outcome. Regulatory authorities are looking to improve the regulatory process. 
Improved knowledge on interactions with food, on drug and formulation behaviour in specific 
patient populations, and in different parts of the GI tract will help achieve this goal. This will be 
further enhanced by icreased reproducibility and comparability and through computational 
models that can predict drug and formulation behaviour. Of note, institutional policies often do 
not allow the formal participation of regulatory authorities. Nevertheless, the Action plans to 
interact with regulatory authoritiy which will take up a role as external advisor and provide input 
from the regulatory point-of-view. In addition, the Action will involve experts from regulatory 
authorities as member(s) who will provide regulatory insight.  
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Table 1 Stakeholder analysis of the UNGAP network 
Stakeholder  Interests  Goals  Tools  
Biopharmaceutical 
and formulation 
scientists, 
computational 
modellers 
New knowledge, 
protocols and 
best practices, 
new simulation 
tools 
To understand 
absorption, to 
improve drug 
development 
and treatment  
Network meetings, Short-Term 
Scientific Missions (STSMs), 
workshops, training school, 
conference, seminars, webinars, 
publications 
Technology 
developers  
Interaction with 
end-users 
New or 
improved 
technology 
Network meetings, STSMs, 
workshops, training school, 
conference, seminars, webinars, 
newsletters,  
Pharmaceutical 
industry  
New knowledge, 
protocols and 
best practices, 
new simulation 
tools 
To improve the 
drug 
development 
process   
Network meetings, STSMs, 
workshops, training school, 
conference, seminars, webinars, 
newsletter, factsheets, 
publications 
Clinicians & 
patients 
New knowledge, 
pharmacometric 
models  
To improve 
dosing and 
treatment 
Conference, seminars, webinars, 
newsletters, factsheets, posters, 
leaflets, publications 
Regulatory 
authority  
New knowledge, 
protocols and 
best practices, 
new simulation 
tools 
To improve the 
regulatory 
process 
Network meetings, STSMs, 
workshops, training school, 
conference, seminars, webinars, 
newsletter, factsheets, 
publications 
II) DISSEMINATION AND/OR EXPLOITATION PLAN 
A specific cross-cutting WG will be dedicated to communication, dissemination and 
exploitation in order to maximise the impact of the Action. To this end, WG 5 leaders will closely 
interact with WG 1-4 leaders (to be appointed, see 3.2) and the Action Management 
Committee (MC). Dissemination and exploitation plans are discussed in detail below. 
Dissemination 
The Action aims to disseminate its key findings to all stakeholders mentioned in Table 1, by 
using a balanced and varied dissemination strategy. The following dissemination tools will be 
used:  
 Publications in peer-reviewed scientific journals present the most obvious dissemination 
route. To widen exposure, the Action will adopt the Horizon 2020 open access policy.  
 Thematic hands-on workshops and a training school will be organised. Participants will 
be able to gain technical expertise and exchange best practices. It will also be an opportunity 
for technology developers to showcase their latest innovations.  
 The Action will interact with other networks (see 1.4.2) to wider promote and disseminate 
the Action.  
 Regular seminars and webinars will be organised. Targeted communication through the 
institutions and professional network of Action members will be used to advertise these 
events to external stakeholders such as clinicians and regulatory agencies.  
 A website www.UNGAP.eu with an open and closed part for external and internal 
communication respectively will be made.  
 The Network will be active on social media. A Twitter account will be used to send short 
messages and keep in touch with the latest developments. LinkedIn will be used to 
communicate to professionals outside the Network.  
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 A newsletter highlighting Network activities and findings will be published twice a year. 
Interested persons will be able to subscribe to the newsletter via the website.  
 Posters and leaflets will be used to promote the Action, attract additional members and 
highlight achievements. They will also be used for communication to clinicians and patients. 
 Factsheets will be made to communicate findings, best practices and recommendations in 
a condensed format.  
 The Action will target mainstream media through institutional press and media services.  
 The Action will organise a final conference to highlight and disseminate the results of 
the Action. 
Exploitation 
Since the Action focusses on networking and establishing new connections and not on 
development of a specific product, a policy will be adopted to facilitate the exchange of 
researchers and know-how between the partners in the spirit of open science and open 
innovation. Within the Network, expert advise on the protection and exploitation of IPwill be 
available. The main exploitable results from the Action are the new insights obtained through 
WG discussions, knowledge defragmentation and the elaboration of new collaborative 
research projects between Network members. The development of new tools and models 
presents another exploitable Action outcome. This will be particularly important for in silico 
models where there is a high pace and relatively low development cost, making the creation 
of new models feasible within the timeframe of the proposed Action. Exploitation will be done 
in collaboration with the developers. The Action will strive to exploit and disseminate the 
models as wide and as efficient as possible.  
Indirectly, the Action will also contribute to advances in specific research projects (funded 
through other sources) that may lead to exploitable results. When applicable, protection of 
intellectual property (IP) for a given project will be done in accordance with the project funding 
agencies’ specific rules and guidelines. In case sensitive material with respect to intellectual 
property rights (IPR) or confidentiality is presented during meetings, non-disclosure 
agreements will be used. 
C) POTENTIAL FOR INNOVATION VERSUS RISK LEVEL 
I) POTENTIAL FOR SCIENTIFIC, TECHNOLOGICAL AND/OR SOCIOECONOMIC 
INNOVATION BREAKTHROUGHS 
In order to establish a coherent Network with maximal chances of achieving significant 
progress and potentially a real breakthrough in a field as diverse and complex as drug 
disposition, we chose to limit our scope to oral drug absorption. The main objective is to make 
substantial progress in selected key areas and as such advance the field as a whole. 
New insight into the effects of (patho)physiological variables on oral drug absorption can 
be used to tailor dosing schemes to specific populations, such as pediatric or geriatric patients. 
A better understanding of the regional differences along the GI tract will contribute to the 
design of formulations that efficiently exploit the GI environment to obtain optimal absorption 
at the desired site. For example, development of colon targeting drugs will benefit from a better 
understanding of formulation behaviour in the colon, but also the upper parts of the GI tract. 
Information on the specific behaviour of advanced formulations can help explain why 
certain formulations succeed or fail. This will make formulation design more knowledge-driven 
and efficient. Exploitable knowledge on food effects and the interaction of food 
components with the gut, drugs and formulations can improve drug safety and efficacy. It 
is also of particular interest to drug developers working with lipophilic drugs, like many drug 
candidates currently in development, since food intake can affect the solubility as well as the 
permeability. Although the challenges are major, the potential impact on improving drug 
development and treatment is large. The risk of not achieving significant progress in this area 
is reduced by the presence of experts in gastroenterology, biopharmacy, drug development, 
technology development as well as a major company from the food industry in the Network. 
Dissemination of protocols and best practices will improve comparability and 
reproducibility of results and boost the overall confidence level of knowledge on oral drug 
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absorption. This will not lead to direct innovation, but will have a beneficial effect on the quality 
of future research projects and innovations resulting from them. 
Technological advancements can be divided into new applications and improvements of 
existing applications. The latter is expected to have a medium to high potential for innovation, 
depending on the extent of the improvements made, but also a lower risk, since there is already 
a foundation to build on. In contrast, new applications have a higher innovation potential, 
including possible commercialisation in the future, but are more difficult to achieve within the 
time-frame of the Action.  
Development or improvement of computational models is realistic within the Action time-
frame, because of the high speed of developments in this field and the Action plans to involve 
experienced software developer(s). A lack of data on specific patient populations and the 
effects of food components, which are focus areas of WG 1 and 4 respectively, presents the 
biggest limitation in the application of computational models. The data obtained from current 
research projects on food effects and specific patient populations will contribute to the 
development or improvement of computational models, which in turn can be used by 
pharmaceutical industry or clinicians, for improved drug development or optimised dosing 
respectively, thus having a mainly economical or mainly societal impact.  
Finally, on an individual level, the Action will have impact on two specific things. Firstly, 
elaborating new research project proposals is highly feasible. The focus on specific 
challenges and the multidisciplinary mix of Network participants make the Network ideally 
suited to respond to specific calls and develop collaborative research projects. All Network 
proposers have a successful track record in securing (international) funding for research 
projects. Secondly, the Action will allow ECIs to expand their professional network, which 
is expected to have a beneficial effect on their careers. 
3) IMPLEMENTATION 
A) DESCRIPTION OF THE WORK PLAN 
I) DESCRIPTION OF WORKING GROUPS 
The Action will consist of 5 WGs that are all interconnected (Fig. 1). A description of the WGs 
follows hereafter. Milestones and deliverables are listed in Table 2.  
WG 1. Specific patient populations.  
Objective: The objective of this WG is to acquire a profound insight into (patho)physiological 
variables influencing oral drug absorption in specific patient populations.  
Tasks & activities:  
 Publish a review on the state-of-the-art and the remaining knowledge gaps on intestinal 
drug absorption in specific patient populations.  
 Collect and exchange emerging knowledge on drug absorption in specific patient 
populations.  
 Organise STSMs with specific attention for interdisciplinary and inter-WG mobility. 
 Publish guidelines and protocols to study drug absorption in specific patient populations. 
 Organise 2 hands-on workshops on methods to study (patho)physiology and intestinal drug 
absorption in specific patient populations (in collaboration with WG 2-5). 
 Organise a training school on intestinal drug absorption (together with WG 2-5). 
 Publish a position paper with an outlook on the future of intestinal drug absorption research 
(together with WG 2-5). 
 Develop new collaborative research project proposals (Target: 2 submitted proposals per 
WG) 
WG 2. Regional differences along the GI tract.  
Objective: The objective of this WG is to acquire a deeper insight into the regional differences 
along the GI tract, which is particularly important for extended release formulations, which 
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release the drug over a wider area, and for formulations targeting specific regions of the gut, 
for example the colon.  
Tasks & activities: 
 Publish a review on the state-of-the-art and the remaining knowledge gaps concerning 
differences in intestinal drug absorption along the length of the GI tract. 
 Collect and exchange emerging information on regional differences in the gut in terms of 
fluid composition, membrane permeability, transporter and enzyme expression, and 
absorptive capacity.  
 Organise STSMs with specific attention for researcher mobility between labs focussing on 
different parts of the GI tract. 
 Publish guidelines and protocols with a focus on how methods can be used to study different 
parts of the gut and how data can be compared and integrated. 
 Organise 2 hands-on workshops focussing on methodology and data interpretation (in 
collaboration with WG 1, 3, 4 and 5). 
 Organise a training school on intestinal drug absorption (together with WG 1, 3, 4 and 5). 
 Publish a position paper with an outlook on the future of intestinal drug absorption research 
(together with WG 1, 3, 4 and 5). 
 Develop new collaborative research project proposals (Target: 2 submitted proposals per 
WG). 
WG 3. Intraluminal behaviour of advanced formulations.  
Objective: The objective of this WG is to deepen our understanding of the specific behaviour 
of advanced formulations, such as supersaturating formulations, extended release 
formulations, lipid-based drug delivery systems and nanoparticles.  
Tasks & activities: 
 Publish a review on the state-of-the-art and the remaining knowledge gaps concerning the 
intraluminal behaviour of advanced formulations.  
 Collect and exchange emerging knowledge on the intaluminal behaviour of existing 
advanced formulations and on new types of enabling formulations.  
 Organise STSMs with specific attention for mobility between different WGs. 
 Publish guidelines and protocols for formulation design. 
 Organise a training school on intestinal drug absorption (together with WG 1, 2, 4 and 5). 
 Publish a position paper with an outlook on the future of intestinal drug absorption research 
(together with WG 1, 2, 4 and 5). 
 Develop new collaborative research project proposals (Target: 2 submitted proposals per 
WG). 
WG 4. Food-drug interface.  
Objective: The objective of this WG is to study the effects of food intake and food components 
on the intraluminal behaviour of drugs and formulations.  
Tasks & activities: 
 Publish a review on the state-of-the-art and the remaining knowledge gaps concerning food 
effects and the interactions between food components and oral formulations.  
 Collect and exchange emerging knowledge on food effects and food-drug interactions.  
 Organise STSMs with specific attention for mobility between different WGs. 
 Publish guidelines and protocols to study food effects and food-drug interactions. 
 Organise 2 hands-on workshops on the interface between food and pharmaceutical science 
(in collaboration with WG 1-3 and 5).  
 Organise a training school on intestinal drug absorption (together with WG 1-3 and 5). 
 Publish a position paper with an outlook on the future of intestinal drug absorption research 
(together with WG 1-3 and 5). 
 Develop new collaborative research project proposals (Target: 2 submitted proposals per 
WG). 
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WG 5. Dissemination, exploitation and public engagement.  
Objective: The objective of this WG is to coordinate all communication, dissemination and 
exploitation activities to assure an efficient flow of information to all stakeholders while at the 
same time respecting and protecting the IP of all parties involved.  
Tasks & activities: 
 Establish a procedure for handling confidential or IP-sensitive information.  
 Coordinate the publication of reviews, protocols and the position paper. 
 Use newsletters, posters, factsheets and leaflets to present findings in a condensed format.  
 Set-up and maintain a website as a dissemination and internal communication platform. 
 Organise webinars, seminars and a conference on oral drug absorption. 
 Coordinate the organisation of a training school on intestinal drug absorption (together with 
WG 1-4). 
 Contribute to the elaboration of new collaborative research projects (together with WG 1-
4). 
 Develop new collaborative research project proposals (Target: 2 submitted proposals per 
WG). 
 
Table 2 list of milestones and deliverables 
Description Month Milestone Deliverable  
1st MC meeting, assignment of WG leaders and other 
functions 
1 1 1 
Website online and social media profiles active 6 2 2 
Publication of WG reviews  18 / 3 
1st STSMs 18 3 / 
Catalogue of protocols and best practice guidelines  18 / 4 
1st workshop   18 4 5 
Training school (1 for the entire Action) 30 5 6 
Publication of joint position paper  40 / 7 
2nd workshop  40 6 8 
UNGAP conference 44 7 9 
II) GANTT DIAGRAM 
Description Project month 
 1 3 6 9 12 15 18 21 24 27 30 33 36 40 42 44 48 
MC meeting X  X  X  X  X  X  X  X  X 
WG meeting  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  X  
Website 
online 
  X               
Reviews (4)       X           
1st STSMs       X           
Protocol and 
guidelines 
catalogue 
      X           
1st workshop       X           
Training 
school 
          X       
Position 
paper  
             X    
2nd 
workshop 
             X    
UNGAP 
conference 
               X  
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III) RISK AND CONTINGENCY PLANS 
Description of Risk Proposed mitigation measures 
No input for protocol and 
best practice catalogue 
Rewarding active participation in Network activities through 
reimbursement schemes. The goal for each Network member is 
to submit at least 2 documents. 
Incoherent WG work plan  Work plan adaptation by WG leaders and MC 
Insufficient WG progress (i) Recruitment of additional members to WG. (ii) Intensify 
collaboration with Action members from other WGs. 
Dormant Action 
members 
(i) Financial incentives (through reimbursement schemes) for 
active Network-members. (ii) Replacement of dormant members  
Exploitation and/or 
dissemination conflict  
(i) Establish a procedure to avoid conflicts. (ii) Conflicts handled 
by WG 5 leaders and MC to negotiate a solution 
Insufficient impact Impact maximization through pro-active interaction with 
stakeholders, coordinated by WG 5 leaders.  
Insufficient gender 
balance 
Pro-active recruitment aiming for 40% of the under-represented 
category. 
Conflict between 
scientific quality and 
COST policy 
(i) Search for a compromise by MC. (ii) If no compromise can be 
reached, quality will be preferred.  
Withdrawal by a network 
member 
All hereto identified network members have expressed their 
commitment. In case of withdrawal of a MC member, WG leader 
or task responsible, a suitable replacement will be identified (i) 
within UNGAP or (ii) via the professional network of other Action 
members. 
Note: Roman numbers refer to the order in which mitigation measures will be taken. 
B) MANAGEMENT STRUCTURES AND PROCEDURES 
Management Committee: The MC will be formed and will function according to the Rules and 
Procedures described in COST 4112/13 “COST Rules for Participation in and Implementation 
of COST Activities”. The Action Chair is responsible for management and coordination of the 
Action. The MC consisting of the Chair, Vice-Chair and max. 2 representatives per country, is 
the primary decision-making body and will meet twice a year to oversee all activities carried 
out under this Action. At least one MC meeting per year will be face to face and organised in 
conjunction with a meeting of the WGs. If deemed feasible, the other meeting may be done 
via teleconference to restrict travel demands for MC members. The MC will carry out the 
following tasks: (i) prepare and manage the annual detailed work and budget plan, (ii) create 
a set of rules for the WGs to carry out their activities, (iii) allocate funds to activities according 
to Grant Period goals of every WG, (iv) monitor progress in the WGs, based on the milestones 
and deliverables described in Table 2, interaction with WG Leaders and annual WG progress 
reports, and take corrective action when necessary, (v) coordinate the organisation of 
meetings, workshops, training school and conference, and (vi) coordinate interactions with 
external stakeholders.  
Working Groups (WGs): WG 1-4 have a scientific focus, with each group acting as a 
coordination node for their respective research topic. WG 5 will entail all dissemination, 
exploitation and public engagement activities and will as such extensively interact with WG 1-
4. Each WG will be organised by two WG Leaders who will be nominated during the first MC 
meeting. WG Leaders will identify additional Task Responsible persons to carry out specific 
tasks (organisation of workshops, coordinate STSM programme, website maintenance). The 
WG Leaders will oversee the organisation of these activities and will act as liaison with the 
MC. In addition, they will be responsible for submitting an annual report to the MC to evaluate 
progress on the milestones, deliverables and the different tasks and activities. The WG 
Leaders will meet face to face at least once a year in conjunction with an MC meeting. Task 
Responsible persons may be invited to this meeting, when their participation is deemed 
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necessary. Ordinary WG meetings (every three months) will be done via teleconference as 
much as possible to reduce travel and time demands. Face to face WG meetings will be 
organised on 1 location to promote interactions between WGs. Meetings will be planned by 
the WG Leaders, following the approval of the MC and the Action Science Officer.  
C) NETWORK AS A WHOLE 
Several of the world’s leading pharmaceutical companies will be involved in the Network, in 
addition to several gastroenterologists and a large number of pharmaceutical, biological 
and biomedical scientists. The consortium will contain well established as well as upcoming 
research groups and will cover various disciplines including biopharmacy, gastroenterology, 
physical chemistry, drug delivery, (bio)imaging, and pharmacometrics. All research groups 
participating in this Action will have (inter)national funding for their own research programmes. 
The presence of technology and computational software developers will ensure promotion 
of the latest products, their proper use and the creation of an efficient feedback loop from end-
users to developers. Finally, an external advise will be provided by representative(s) from 
regulatory authority, in line with the institutional policy. The network in composition as 
described above will guarantee that the planned work will be carried out successfully and that 
significant impact will be achieved.  
The Action plans also to establish links with the oral drug absorption research communities in 
Australia and the USA. The researchers from Australia are leaders in the use of lipid-based 
systems, dendrimers and nanomaterials for drug delivery and experts in synchrotron small 
angle X-ray scattering, and the researchers from the USA,  authorities in the fields of drug 
solubility, drug transport, and drug absorption, and  the representatives from major 
pharmaceutical companies. The international members will increase the Network’s scientific 
critical mass and allow the Network to achieve worldwide impact. In return, they will be invited 
to attend Network events and temporarily host ECIs and other researchers. 
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